Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Press release, Helsinki, 16 December 2025 at 9 AM (EET)
Finnish Private Clinic Group Orders Two Nexstim NBS 6 Systems
Nexstim Plc ("Nexstim" or "Company") has received an order for two NBS 6 therapy systems from a customer in Finland. The customer is a private healthcare provider that is replacing their current Nexstim therapy systems with new NBS 6 systems.
In therapy, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain. The NBS 6 enables Nexstim’s unique E-field navigated TMS technology to be used more easily than ever before. Part of this new product generation is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer’s research or clinical interests.
Mikko Karvinen, CEO of Nexstim, comments: “We are happy to see our customers gain positive experiences with our products, and excited to continue the treatment journey with this Finnish private healthcare provider. Finland has always been an important home market for Nexstim, and we are proud of our strong customer base. This order demonstrates the growing confidence in our technology in therapy applications and reflects our shared commitment to improving patient care.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE-marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com